Investigation of the Influence of the Human Microbiome on Giant Cell Arteritis
ConditionGiant Cell Arteritis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Bonn
About this trial
The longitudinal observational study aims to assess the impact of the microbiome especially the gut-microbiome in the emergence and course of giant cell arteritis (abbr. GCA) patients. At diagnosis and 6 month follow up we will analyze the oral, blood and gut microbiome from GCA patients and healthy controls. Thereby identified potential candidate biota will be further analyzed for possible interactions and influence on the immune system.
Eligibility criteria
Qualifiers
None
Disqualifiers
chronic infection (viral, fungi, bacteria) including human immunodeficiency viruses, Hepatitis B/C
acute infection with usage of antibiotics less then 90 days before screening
major gastro-intestinal surgery <5 years from screening
gastro-intestinal bleeding <90 days before screening
Trial design
Treatments tested in this trial
- Analysis of blood and microbiome samples (stool, oral lavage)
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov